IM Cannabis Corp. (IMCC) - Form 20-F Summary
Business Context and Reporting Period
Company: IM Cannabis Corp. (IMCC)
Reporting Period: Fiscal Year Ended December 31, 2024
Jurisdiction: British Columbia, Canada (Foreign Private Issuer)
Operations: International medical cannabis company focused on Israel and Germany. The Company exited its Canadian operations (Trichome) in 2022, which are reported as discontinued operations. In 2024, the Company deconsolidated Oranim Plus Pharm Ltd. due to a failed transaction settlement.
Key Events:
- Implemented a 6:1 reverse share consolidation on July 12, 2024, to regain Nasdaq listing compliance.
- Completed a non-brokered private placement in November 2024 raising $2.1 million (CAD).
- Settled a debt obligation with CEO Oren Shuster via issuance of shares and pre-funded warrants valued at $560,000 (USD).
- Changed auditors from Kost Forer Gabbay & Kasierer to Fahn Kanne & Co. Grant Thornton Israel effective January 16, 2025.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (CAD '000s) | 2023 (CAD '000s) |
|---|---|---|
| Revenue | $54,031 | $48,804 |
| Cost of Revenue | $45,580 | $37,974 |
| Gross Profit | $8,451 | $9,846 |
| Operating Loss | $(10,234) | $(12,792) |
| Net Loss (Continuing Ops) | $(11,771) | $(10,228) |
| Cash and Cash Equivalents | $863 | $1,813 |
| Total Debt (Current + Non-Current) | $15,611 | $12,513 |
| Working Capital | $(11,554) | $(8,581) |
Note: All figures in Canadian Dollars (CAD) in thousands, except per share data. The filing does not provide a specific "Net Profit" figure as the company reported a Net Loss.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 10.7% to $54.0 million, driven primarily by a 183% increase in German revenue ($15.5M vs $5.5M in 2023) following the April 2024 legalization of cannabis in Germany. Israeli revenue declined to $38.5M from $43.3M.
- Cost Structure: Cost of revenue increased by 20% to $45.6M, compressing the gross margin from 20.2% in 2023 to 15.6% in 2024.
- Deconsolidation: The Company deconsolidated Oranim Plus Pharm Ltd. in April 2024, recording a $2.7M expense related to the transaction reversal.
- Capital Structure: Issued 742,517 units in November 2024 and converted $2.1M of existing debt into convertible debentures in May 2024.
Guidance, Outlook, and Risks
Outlook: Management expects to achieve profitability in 2025, contingent on successful fundraising and cost-saving measures. The Company is pivoting resources to the German market, anticipating growth from the new regulatory framework.
Going Concern: The auditors have issued an unmodified opinion but included an "Uncertainty Related to Going Concern" paragraph. The Company has negative working capital, accumulated deficits of $258.9M, and negative operating cash flows. Continued operations depend on successful equity/debt financing and revenue growth.
Key Risks:
- Geopolitical: Ongoing "Iron Swords" war in Israel impacting supply chains, employee availability (reservist call-ups), and operational costs.
- Regulatory (Israel): An ongoing "Anti-Dumping" investigation into Canadian cannabis imports could result in tax levies up to 175% on non-cooperative importers.
- Liquidity: High liquidity risk due to negative working capital and reliance on short-term debt extensions.
- Legal: Pending appeals regarding a EUR 948k judgment against Stroakmont (COVID test kits) and a shareholder class action in Canada (35 Oak Holdings).
Investor Verification Checklist
- Going Concern Status: Verify the Company's ability to secure additional financing to cover the $11.5M negative working capital and upcoming debt maturities.
- German Revenue Sustainability: Assess whether the 183% revenue spike in Germany is sustainable or a one-time benefit from regulatory changes.
- Anti-Dumping Investigation: Monitor the final decision by the Israeli Ministry of Treasury regarding tax levies on Canadian imports, which could severely impact margins.
- Debt Maturities: Review the terms of the various short-term loans (e.g., ADI Loan, Mizrahi Facility) and the likelihood of further extensions or refinancing.
- Related Party Transactions: Scrutinize the $560k debt settlement with the CEO and the issuance of pre-funded warrants, noting the requirement for shareholder approval to exercise.